(19)
(11) EP 2 843 056 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
26.06.2019 Bulletin 2019/26

(45) Mention of the grant of the patent:
10.04.2019 Bulletin 2019/15

(21) Application number: 13182484.9

(22) Date of filing: 30.08.2013
(51) International Patent Classification (IPC): 
C12Q 1/6883(2018.01)

(54)

Risk markers for cardiovascular disease in patients with chronic kidney disease

Risikomarker für kardiovaskuläre Erkrankung bei Patienten mit chronischer Nierenerkrankung

Marqueurs de risque de maladie cardiovasculaire chez des patients atteints de maladie rénale chronique


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(43) Date of publication of application:
04.03.2015 Bulletin 2015/10

(73) Proprietor: GENINCODE UK, Ltd.
Manchester M2 3DE (GB)

(72) Inventors:
  • Salas, Eduardo
    08950 Esplugues de Llobregat (Barcelona) (ES)
  • Pich, Sara
    08950 Esplugues de Llobregat (Barcelona) (ES)
  • Arias, Manuel
    08950 Esplugues de Llobregat (Barcelona) (ES)
  • Elosua, Roberto
    08950 Esplugues de Llobregat (Barcelona) (ES)
  • Castillo, Sergio
    08950 Esplugues de Llobregat (Barcelona) (ES)

(74) Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)


(56) References cited: : 
EP-A1- 2 264 183
WO-A1-2012/001613
EP-A1- 2 554 679
WO-A2-2008/060618
   
  • PATRICK LINSEL-NITSCHKE ET AL: "Genetic variation in the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) is associated with myocardial infarction in the German population", CLINICAL SCIENCE, vol. 115, no. 10, 1 November 2008 (2008-11-01), page 309, XP055013105, ISSN: 0143-5221, DOI: 10.1042/CS20070468
  • ANNABEL Z. WANG ET AL: "Association of SNP rs17465637 on Chromosome 1q41 and rs599839 on 1p13.3 with Myocardial Infarction in an American Caucasian Population", ANNALS OF HUMAN GENETICS, vol. 75, no. 4, 4 April 2011 (2011-04-04), pages 475-482, XP055013117, ISSN: 0003-4800, DOI: 10.1111/j.1469-1809.2011.00646.x
  • YAN YU ET AL: "Evaluation of population impact of candidate polymorphisms for coronary heart disease in the Framingham Heart Study Offspring Cohort", BMC PROCEEDINGS, BIOMED CENTRAL LTD, LONDON UK, vol. 3, no. Suppl 7, 15 December 2009 (2009-12-15), page S118, XP021069893, ISSN: 1753-6561
  • YUMIKO HIURA ET AL: "Validation of the Association of Genetic Variants on Chromosome 9p21 and 1q41 With Myocardial Infarction in a Japanese Population", CIRCULATION JOURNAL, vol. 72, no. 8, 1 August 2008 (2008-08-01) , pages 1213-1217, XP055013121, ISSN: 1346-9843, DOI: 10.1253/circj.72.1213
  • EAGLE K A ET AL: "Summaries of Key Journal Articles", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 55, no. 9, 2 March 2010 (2010-03-02), pages 948-955, XP026921139, ISSN: 0735-1097, DOI: 10.1016/J.JACC.2010.02.001 [retrieved on 2010-02-23]
  • M RAO ET AL: "Cytokine gene polymorphism and progression of renal and cardiovascular diseases", KIDNEY INTERNATIONAL, vol. 72, no. 5, 20 June 2007 (2007-06-20), pages 549-556, XP055087743, ISSN: 0085-2538, DOI: 10.1038/sj.ki.5002391
  • ARKING D E ET AL: "Understanding cardiovascular disease through the lens of genome-wide association studies", TRENDS IN GENETICS, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 25, no. 9, 1 September 2009 (2009-09-01), pages 387-394, XP026564456, ISSN: 0168-9525, DOI: 10.1016/J.TIG.2009.07.007 [retrieved on 2009-08-26]
  • ROBERT CLARKE ET AL: "Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease", NEW ENGLAND JOURNAL OF MEDICINE, vol. 361, no. 26, 24 December 2009 (2009-12-24), pages 2518-2528, XP055023613, ISSN: 0028-4793, DOI: 10.1056/NEJMoa0902604
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).